Switching Outpatients With Bipolar or Schizoaffective Disorders and Substance Abuse From Their Current Antipsychotic to Aripiprazole
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Substance abuse is extremely common in patients with bipolar disorders, although minimal data are available on the treatment of this important clinical population. Aripiprazole is an atypical antipsychotic that is approved for the treatment of mania and that has a novel mechanism of action, acting as a dopamine-2 receptor partial agonist, thereby increasing dopamine release in some parts of the brain and decreasing dopa-mine release in other brain regions. Dopamine release is implicated in substance use, and both dopaminergic agonists and antagonists have been examined for the treatment of substance abuse. To our knowledge, dopa-mine receptor partial agonists have not been investigated for treatment of substance abuse in humans. METHOD: Twenty antipsychotic-treated patients with bipolar or schizoaffective disorder and current substance abuse were switched to open-label aripipra-zole using an overlap and taper method. At baseline, diagnoses were confirmed using the Mini-International Neuropsychiatric Interview based on DSM-IV criteria. Psychiatric symptoms, side effects, and substance use and craving were assessed over 12 weeks. Psychiatric symptoms were assessed with the Hamilton Rating Scale for Depression (HAM-D), Young Mania Rating Scale (YMRS), and Brief Psychiatric Rating Scale (BPRS). Substance craving was assessed with visual analogue scales, and side effects were monitored using the Abnormal Involuntary Movement Scale, Simpson-Angus Scale, Barnes Akathisia Scale, and patient report. Study enrollment was from April 2003 to February 2004. RESULTS: Significant baseline-to-exit improvement in HAM-D (p = .002), YMRS (p = .021), and BPRS (p = .000) scores were observed without a significant change in antipsychotic-induced side effect scales. In 17 participants with current alcohol dependence, significant reductions in dollars spent on alcohol (p = .042) and alcohol craving (p = .003) were found. In 9 participants with cocaine-related disorders, significant reductions in cocaine craving (p = .014), but not use, were found. CONCLUSION: A change to aripiprazole was associated with symptomatic improvement. Limitations of the study include a small sample size, high attrition, and an open-label design. Controlled trials in dual-diagnosis patients are needed to confirm these findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aripiprazole has level 4 evidence to decrease craving of alcohol, but not consumption, and level 4 evidence to decrease cocaine use in polysubstance users.719”
Citations
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“In an open-label study of 20 patients with bipolar disorder or schizoaffective disorder, a switch to aripiprazole resulted in improved depression, mania and BPRS scores as well as reduction in cocaine and alcohol craving, and amount spent on alcohol, but not cocaine use (Brown et al., 2005) (IIb).”
BackgroundThe prevalence and significance of substance use disorders in bipolar type I and II disorder
Cerullo, M. A., & Strakowski, S. M. (2007) · Substance Abuse Treatment, Prevention, and Policy · doi:10.1186/1747-597x-2-29 · Cited by 195
Unique Effects of Clozapine: A Pharmacological Perspective
Khokhar, J. Y., Henricks, A. M., Sullivan, E. D. K., & Green, A. I. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.09.009 · Cited by 182
Treatments for Patients With Dual Diagnosis: A Review
Tiet, Q. Q., & Mausbach, B. (2007) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00336.x · Cited by 169
Metadata
- Authors
- Brown, E. S., Jeffress, J., Liggin, J. D. M., Garza, M., & Beard, L.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- ORCID
- Brown, E. Sherwood
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-06-15
- Volume
- 66
- Issue
- 06
- Pages
- 756-760
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2004252407
- Cited by
- 118
- References
- 0
- Citations by year
- 2024: 3 · 2023: 4 · 2022: 2 · 2021: 5 · 2019: 4 · 2018: 8 · 2017: 7 · 2016: 4 · 2015: 3 · 2014: 6 · 2013: 5 · 2012: 8
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- aripiprazole, bipolar disorder, schizoaffective disorder, substance abuse, dual diagnosis, antipsychotic switching, alcohol craving, cocaine craving, alcoholism, cocaine dependence, mania, depression, antipsychotic adverse effects, akathisia
- MeSH terms
- Aripiprazole, Adult, Ambulatory Care, Bipolar Disorder, Female, Humans, Male, Pilot Projects, Piperazines, Psychiatric Status Rating Scales, Psychotic Disorders, Antipsychotic Agents, Quinolones, Comorbidity, Treatment Outcome, Receptors, Dopamine D2, Diagnosis, Dual (Psychiatry), Dopamine Agonists, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Switching Outpatients With Bipolar or Schizoaffective Disorders and Substance Abuse From Their Current Antipsychotic to Aripiprazole. https://app.cochat.ai/papers/10.4088/jcp.v66n0613
- The paper
- Brown, E. S., Jeffress, J., Liggin, J. D. M., Garza, M., & Beard, L. (2005). Switching Outpatients With Bipolar or Schizoaffective Disorders and Substance Abuse From Their Current Antipsychotic to Aripiprazole. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v66n0613
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.